An Open-Label Study Evaluating the Safety and Tolerability of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Jan 2018
At a glance
- Drugs VC 02 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors ViaCyte
- 03 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 07 Jul 2017 Status changed from not yet recruiting to recruiting.
- 26 May 2017 New trial record